Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets-Reference-Cited by-同舟云学术

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets

Published:2017-09-27 Issue:22 Volume:1 Page:1884-1890
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Bolen Christopher R.¹,McCord Ronald²,Huet Sarah³⁴,Frampton Garrett M.⁵,Bourgon Richard¹,Jardin Fabrice⁶,Dartigues Peggy⁷,Punnoose Elizabeth A.²,Szafer-Glusman Edith²,Xerri Luc⁸⁹,Sujobert Pierre³⁴,Salles Gilles³⁴,Venstrom Jeffrey M.²

Affiliation:

1. Bioinformatics and

2. Oncology Biomarker Development, Genentech, South San Francisco, CA;

3. Laboratory of Hematology, Lyon-Sud Hospital Center, Pierre-Benite, France;

4. Cancer Research Center of Lyon, INSERM U1052, Unité Mixte de Recherche Centre National de la Recherche Scientifique 5286, Lyon, France;

5. Foundation Medicine, Inc, Cambridge, MA;

6. Henri Becquerel Center, Rouen, France;

7. Gustave Roussy Institute, Villejuif, France; and

8. Department of Bio-Pathology, Hematology, and Tumor Immunology, and

9. Paoli-Calmettes Institute, Aix-Marseille University, Marseille, France

Abstract

Key Points Low mutation load is associated with a benefit from rituximab maintenance. The Teff signature correlates with high mutation load, is prognostic, and may distinguish immunologically distinct FL subgroups.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/22/1884/877702/advances000786.pdf

Reference39 articles.

1. Molecular and genetic properties of tumors associated with local immune cytolytic activity;Rooney;Cell,2015

2. Neoantigens in cancer immunotherapy;Schumacher;Science,2015

3. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer;Rizvi;Science,2015

4. Mutational landscape and significance across 12 major cancer types;Kandoth;Nature,2013

5. Genetic basis for clinical response to CTLA-4 blockade in melanoma;Snyder;N Engl J Med,2014

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03;2024-08-11

2. The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors;Cancer Research Communications;2024-08-01

3. Impact of LAG-3/FGL1 pathway on immune evasive contexture and clinical outcomes in advanced urothelial carcinoma;Journal for ImmunoTherapy of Cancer;2024-07

4. Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma;Clinical Cancer Research;2024-06-05

5. Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target;Blood Cancer Journal;2024-05-02